New pill shows promise for tough blood cancers in early trial
NCT ID NCT05347225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for signs that the drug is shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital-hematology department ( Site 1002)
Guangzhou, Guangdong, 510080, China
-
Henan Cancer Hospital-hematology department ( Site 1003)
Zhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital ( Site 1004)
Changsha, Hunan, 410013, China
-
Institute of hematology&blood disease hospital-Hematology ( Site 1001)
Tianjin, Tianjin Municipality, 301636, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007)
Guangzhou, Guangdong, 511400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?